Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.
Journal of psychopharmacology (Oxford, England) July 1, 2016 Deborah C. Mash, Barbara Ameer, Delphine Prou et al. 29 citations
Oral noribogaine dose dependently reduced naloxone-precipitated morphine withdrawal signs in mice by up to 88% with an ED50 of 13 mg/kg. Noribogaine showed high brain penetration with a brain/blood ratio of 7±1 across all doses tested. In rats, noribogaine up to 100 mg/kg did not produce conditioned place preference, indicating it is not perceived as a hedonic stimulus. Retrospective review of ibogaine studies suggests that differences in route of administration and testing time explain literature discrepancies. Noribogaine, not ibogaine, likely mediates withdrawal-blocking effects and may offer a non-addictive alternative to opiate replacement therapies.